Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 19Gastrointestinal 3NET 2Thoracic 1Other 1Head & Neck 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Neuroendocrine Tumors 169Carcinoid Tumor 27Carcinoma, Neuroendocrine 22Neoplasms 16Gastro-enteropancreatic neuroendocrine tumor 16Adenoma, Islet Cell 15Pancreatic Neoplasms 12Neoplasm Metastasis 10Pheochromocytoma 8Paraganglioma 8Sarcoma 7Colorectal Neoplasms 7Carcinoma 7Neuroectodermal Tumors, Primitive 6Neuroblastoma 6Gastrointestinal Neoplasms 6Vipoma 5Somatostatinoma 5Gastrinoma 5Cholangiocarcinoma 5Carcinoma, Islet Cell 5Breast Neoplasms 5Small Cell Lung Carcinoma 4Serotonin Syndrome 4Digestive System Neoplasms 4Anus Neoplasms 4Thyroid Neoplasms 3Salivary Gland Neoplasms 3Ovarian Neoplasms 3Neoplasms by Site 3

Interventions

motesanib diphosphate 1batifiban 1Sorafenib 1Octreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Glucagonoma × NET × Clear all
NCT00427349 2023-07-05

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Completed
46 enrolled 7 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT00131911 2014-11-17

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Completed
93 enrolled 10 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡